Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 70

1.

Phase I safety, pharmacokinetic and pharmacodynamic study of the poly (ADP-ribose) polymerase inhibitor veliparib with irinotecan in patients with advanced tumors.

LoRusso PM, Li J, Burger A, Heilbrun LK, Sausville E, Boerner S, Smith D, Pilat MJ, Zhang J, Tolaney S, Cleary JM, Chen A, Rubinstein L, Boerner JL, Bowditch A, Cai D, Bell T, Wolanski A, Marrero A, Zhang Y, Ji JJ, Ferry-Galow K, Kinders R, Parchment RE, Shapiro GI.

Clin Cancer Res. 2016 Feb 3. pii: clincanres.0652.2015. [Epub ahead of print]

PMID:
26842236
2.

Human CD34(+) progenitor hematopoiesis in liquid culture for in vitro assessment of drug-induced myelotoxicity.

Guo L, Hamre J 3rd, Davis M, Parchment RE.

Toxicol In Vitro. 2016 Mar;31:103-13. doi: 10.1016/j.tiv.2015.11.017. Epub 2015 Nov 23.

PMID:
26616282
3.

Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use.

Srivastava AK, Jaganathan S, Stephen L, Hollingshead MG, Layhee A, Damour E, Govindharajulu JP, Donohue J, Esposito D, Mapes JP, Kinders RJ, Takebe N, Tomaszewski JE, Kummar S, Doroshow JH, Parchment RE.

Clin Cancer Res. 2015 Oct 7. [Epub ahead of print]

PMID:
26446940
4.

Implementation of validated pharmacodynamic assays in multiple laboratories: challenges, successes, and limitations.

Kinders R, Ferry-Galow K, Wang L, Srivastava AK, Ji JJ, Parchment RE.

Clin Cancer Res. 2014 May 15;20(10):2578-86. doi: 10.1158/1078-0432.CCR-14-0476.

5.

Validation of a hypoxia-inducible factor-1 alpha specimen collection procedure and quantitative enzyme-linked immunosorbent assay in solid tumor tissues.

Park SR, Kinders RJ, Khin S, Hollingshead M, Antony S, Parchment RE, Tomaszewski JE, Kummar S, Doroshow JH.

Anal Biochem. 2014 Aug 15;459:1-11. doi: 10.1016/j.ab.2014.04.025. Epub 2014 May 4.

PMID:
24799347
6.

Analyses of the combination of 6-MP and dasatinib in cell culture.

Kaur G, Behrsing H, Parchment RE, Millin MD, Teicher BA.

Int J Oncol. 2013 Jul;43(1):13-22. doi: 10.3892/ijo.2013.1930. Epub 2013 May 2.

7.

Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissues.

Pfister TD, Hollingshead M, Kinders RJ, Zhang Y, Evrard YA, Ji J, Khin SA, Borgel S, Stotler H, Carter J, Divelbiss R, Kummar S, Pommier Y, Parchment RE, Tomaszewski JE, Doroshow JH.

PLoS One. 2012;7(12):e50494. doi: 10.1371/journal.pone.0050494. Epub 2012 Dec 28.

8.
9.

Advances in using PARP inhibitors to treat cancer.

Kummar S, Chen A, Parchment RE, Kinders RJ, Ji J, Tomaszewski JE, Doroshow JH.

BMC Med. 2012 Mar 9;10:25. doi: 10.1186/1741-7015-10-25. Review.

10.

A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas.

Kummar S, Ji J, Morgan R, Lenz HJ, Puhalla SL, Belani CP, Gandara DR, Allen D, Kiesel B, Beumer JH, Newman EM, Rubinstein L, Chen A, Zhang Y, Wang L, Kinders RJ, Parchment RE, Tomaszewski JE, Doroshow JH.

Clin Cancer Res. 2012 Mar 15;18(6):1726-34. doi: 10.1158/1078-0432.CCR-11-2821. Epub 2012 Feb 3.

11.

Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells.

Ji J, Kinders RJ, Zhang Y, Rubinstein L, Kummar S, Parchment RE, Tomaszewski JE, Doroshow JH.

PLoS One. 2011;6(10):e26152. doi: 10.1371/journal.pone.0026152. Epub 2011 Oct 10.

12.

Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.

Kummar S, Chen A, Ji J, Zhang Y, Reid JM, Ames M, Jia L, Weil M, Speranza G, Murgo AJ, Kinders R, Wang L, Parchment RE, Carter J, Stotler H, Rubinstein L, Hollingshead M, Melillo G, Pommier Y, Bonner W, Tomaszewski JE, Doroshow JH.

Cancer Res. 2011 Sep 1;71(17):5626-34. doi: 10.1158/0008-5472.CAN-11-1227. Epub 2011 Jul 27.

13.

Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity.

Kinders RJ, Hollingshead M, Lawrence S, Ji J, Tabb B, Bonner WM, Pommier Y, Rubinstein L, Evrard YA, Parchment RE, Tomaszewski J, Doroshow JH; National Cancer Institute Phase 0 Clinical Trials Team.

Clin Cancer Res. 2010 Nov 15;16(22):5447-57. doi: 10.1158/1078-0432.CCR-09-3076. Epub 2010 Oct 5.

14.

Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers.

Redon CE, Nakamura AJ, Zhang YW, Ji JJ, Bonner WM, Kinders RJ, Parchment RE, Doroshow JH, Pommier Y.

Clin Cancer Res. 2010 Sep 15;16(18):4532-42. doi: 10.1158/1078-0432.CCR-10-0523. Epub 2010 Sep 7. Review.

15.

The statistics of phase 0 trials.

Rubinstein LV, Steinberg SM, Kummar S, Kinders R, Parchment RE, Murgo AJ, Tomaszewski JE, Doroshow JH.

Stat Med. 2010 May 10;29(10):1072-6. doi: 10.1002/sim.3840.

16.

Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells.

Wang LH, Pfister TD, Parchment RE, Kummar S, Rubinstein L, Evrard YA, Gutierrez ME, Murgo AJ, Tomaszewski JE, Doroshow JH, Kinders RJ.

Clin Cancer Res. 2010 Feb 1;16(3):1073-84. doi: 10.1158/1078-0432.CCR-09-2799. Epub 2010 Jan 26.

17.

In vitro comparison of O4-benzylfolate modulated, BCNU-induced toxicity in human bone marrow using CFU-GM and tumor cell lines.

Behrsing HP, Furniss MJ, Robillard KA, Tomaszewski JE, Parchment RE.

Cancer Chemother Pharmacol. 2010 May;65(6):1083-91. doi: 10.1007/s00280-009-1113-7. Epub 2009 Aug 29.

PMID:
19727731
18.

Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells.

Sei S, Mussio JK, Yang QE, Nagashima K, Parchment RE, Coffey MC, Shoemaker RH, Tomaszewski JE.

Mol Cancer. 2009 Jul 14;8:47. doi: 10.1186/1476-4598-8-47.

19.

Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity.

Pfister TD, Reinhold WC, Agama K, Gupta S, Khin SA, Kinders RJ, Parchment RE, Tomaszewski JE, Doroshow JH, Pommier Y.

Mol Cancer Ther. 2009 Jul;8(7):1878-84. doi: 10.1158/1535-7163.MCT-09-0016. Epub 2009 Jul 7.

20.

Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.

Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, Ji J, Monks A, Low JA, Chen A, Murgo AJ, Collins J, Steinberg SM, Eliopoulos H, Giranda VL, Gordon G, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH.

J Clin Oncol. 2009 Jun 1;27(16):2705-11. doi: 10.1200/JCO.2008.19.7681. Epub 2009 Apr 13.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk